跳至主要内容
临床试验/EUCTR2020-002873-88-IE
EUCTR2020-002873-88-IE进行中(未招募)1 期

Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene - Gene Therapy Trial for Patients with Retinitis Pigmentosa: RPGR

MeiraGTx UK II Limited0 个研究点目标入组 96 人开始时间: 2021年10月15日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
96

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Male or female.
  • 2. 3 years of age or older.
  • 3. Has XLRP (generalized rod-cone dystrophy) confirmed by a retinal specialist and has a predicted disease-causing sequence variant in RPGR confirmed by a sponsor-approved laboratory.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 6
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 90
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Has had ocular surgery within 3 months prior to screening or is anticipated to require ocular surgery within 6 months after the study intervention administration.
  • 2. Any investigational ocular treatment or any other ocular treatment that could confound the interpretation of the efficacy results or affect participant compliance with the visit schedule.
  • 3. Has undergone prior retinal surgery involving the macula, vitrectomy, macular laser photocoagulation, external-beam radiation therapy, transpupillary thermotherapy, glaucoma filtration surgery or corneal surgery (except cataract surgery).
  • 4. History of an ocular implant, with the exception of an intraocular lens.

研究者

相似试验

进行中(未招募)
1 期
Gene Therapy Trial for Patients with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defect on Chromosome X.X-Linked Retinitis Pigmentosa caused by mutations in the RPGR geneMedDRA version: 20.0Level: PTClassification code 10038914Term: Retinitis pigmentosaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2020-002873-88-Outside-EU/EEAMeiraGTx UK II Limited
进行中(未招募)
1 期
Gene Therapy Trial for Patients with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defect on Chromosome X.X-Linked Retinitis Pigmentosa caused by mutations in the RPGR geneMedDRA version: 20.0Level: PTClassification code 10038914Term: Retinitis pigmentosaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2020-002873-88-DEMeiraGTx UK II Limited96
尚未招募
3 期
Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene
NL-OMON52296Janssen-Cilag Internation NV3
进行中(未招募)
1 期
Gene Therapy Trial for Patients with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defect on Chromosome X.X-Linked Retinitis Pigmentosa caused by mutations in the RPGR geneMedDRA version: 20.0Level: PTClassification code 10038914Term: Retinitis pigmentosaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2020-002873-88-DKJanssen-Cilag International NV96
进行中(未招募)
1 期
Gene Therapy Trial for Patients with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defect on Chromosome X.X-Linked Retinitis Pigmentosa caused by mutations in the RPGR geneMedDRA version: 20.0Level: PTClassification code 10038914Term: Retinitis pigmentosaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2020-002873-88-FRMeiraGTx UK II Limited66